There is still no cure for osteoarthritis. However, one innovative nanotechnological approach may help send therapeutic agents deeper into the affected cartilage and remain active for longer.
A team of scientists from Toronto and Calgary in Canada may provide a ray of hope for those experiencing the destruction of articular joints—whether knees or facet joints—by osteoarthritis (OA).
OrthoSera GmbH recently announced that the pilot clinical study for their hyperacute serum therapy, hypACT, shows promise for treating osteoarthritis by reversing inflammation and inducing cartilage and bone marrow turnover.
The outcome of total joint arthroplasty (TKA) in the setting of Ehlers-Danlos syndromes (EDS) were compared to those noted among patients undergoing TKA for osteoarthritis (OA). Researchers matched 16 patients (20 knees) with EDS who underwent a TKA
Osteoarthritis is the most common arthritis type, causing pain and stiffness in the joints as cartilage steadily breaks down.
It is often referred to as “wear and tear” arthritis, as opposed to rheumatoid arthritis, which is caused by an immune response.